Sky Century Investment (SKYI) Return on Capital Employed (2025 - 2026)
Sky Century Investment (SKYI) posted quarterly Return on Capital Employed of 26.28% for Q2 2026, down 350.0% year-over-year from 10.51% in Q2 2025, and up 12.84% quarter-over-quarter from 23.29% in Q1 2026.
Sky Century Investment (SKYI) Return on Capital Employed (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has reported Return on Capital Employed for 2 consecutive years, with 26.28% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed fell 350.0% year-over-year to 26.28%; the TTM figure through May 2026 stood at 26.28% (down 350.0% YoY), while the FY2025 annual figure was 39.69%, up 992.0% from the prior year.
- Return on Capital Employed advanced to 26.28% in Q2 2026 per SKYI's latest filing, from 23.29% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 41.75% in Q3 2025 and bottomed at 23.29% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Sky Century Investment | 393,547.71 | 393,283.71 | 26,045.00 | 26.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 26.28% |
| Feb 28, 2026 | 23.29% |
| Nov 30, 2025 | 32.95% |
| Aug 31, 2025 | 41.75% |
| May 31, 2025 | 29.78% |